Trials / Completed
CompletedNCT03798964
The Expression Heparanase in Term and Preterm Placentas
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- Hillel Yaffe Medical Center · Other Government
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
Heparanase is an endo-β-glucuronidase that cleaves heparin-sulfate (HS) side chains of heparan sulfate proteoglycans, an integral constituent of the extra cellular matrix (ECM). This study aims to investigate the association between heparanase expression in the human placenta and preterm birth (PTB) . The investigators hypothesize that an abnormal placentation causes relative placental ischemia that induces higher rates of heparanase expression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Placental analysis | Analysis of placenta to determine expression of heparanase |
Timeline
- Start date
- 2019-01-23
- Primary completion
- 2020-11-24
- Completion
- 2020-11-24
- First posted
- 2019-01-10
- Last updated
- 2022-06-28
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT03798964. Inclusion in this directory is not an endorsement.